Five-year subgroup analysis of tafasitamab plus lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma

被引：0
|
作者：
Duell, Johannes
Abrisqueta, Pau
Dreyling, Martin H.
Gaidano, Gianluca
Barca, Eva Gonzalez
Jurczak, Wojciech
Maddocks, Kami J.
Menne, Tobias
Tournilhac, Olivier
Bakuli, Abhishek
Amin, Aasim
Gurbanov, Konstantin
Salles, Gilles A.
Nagy, Zsolt
机构：
[1] Univ Klin Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[2] Vall Hebron Univ Hosp, Dept Hematol, Vall Hebron Inst Oncol VHIO, Barcelona, Spain
[3] Ludwig Maximilians Univ Hosp, Munich, Germany
[4] Univ Piemonte Orientale, Div Hematol, Dept Translat Med, Novara, Italy
[5] Univ Barcelona, Inst Catal Oncol, Hosp Duran Reynals, IDIBELL, Barcelona, Spain
[6] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Clin Oncol, Krakow, Poland
[7] Ohio State Univ Wexner Med Ctr, Dept Internal Med, Arthur G James Comprehens Canc Ctr, Columbus, OH USA
[8] Newcastle Tyne Hosp, Freeman Hosp, Newcastle Upon Tyne, Tyne & Wear, England
[9] CHU Clermont Ferrand, Clermont Ferrand, France
[10] MorphoSys AG, Planegg, Germany
[11] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[12] Semmelweis Univ, Budapest, Hungary
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19522
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Dull, Johannes
    Maddocks, Kami J.
    Gonzalez-Barca, Eva
    Jurczak, Wojciech
    Liberati, Anna Marina
    Obr, Ales
    Gaidano, Gianluca
    Abrisqueta, Pau
    Andre, Marc
    Dreyling, Martin H.
    Menne, Tobias
    Dirnberger-Hertweck, Maren
    Weirather, Johannes
    Ambarkhane, Sumeet Vijay
    Salles, Gilles A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Estimates of Survival and Life Expectancy with Tafasitamab Plus Lenalidomide in the L-Mind Study Compared with Real-World Standard- of-Care for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Duell, Johannes
    Dreyling, Martin
    Gaidano, Gianluca
    Kalakonda, Nagesh
    Gonzalez Barca, Eva Maria
    Liberati, Anna Marina
    Nagy, Zsolt
    Moik, Daniel
    Vukcevic, Mirko
    Amin, Aasim
    Bakuli, Abhishek
    BLOOD, 2023, 142
  • [23] Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma
    Lu, Q.
    Huang, H.
    Tang, S.
    Wang, Y.
    Yang, D-H
    DRUGS OF TODAY, 2021, 57 (09) : 571 - 580
  • [24] MINDway: A Phase Ib/II Dose Optimization Study to Assess Safety and Pharmacokinetics of Tafasitamab plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Greil, Richard
    Kopeckova, Katerina
    Arcaini, Luca
    Amin, Aasim
    de Graaf, Katrien
    Jegg, Anna-Maria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S356 - S356
  • [25] DIFFUSE LARGE B-CELL LYMPHOMA RESPONDS TO TAFASITAMAB PLUS LENALIDOMIDE
    不详
    CANCER DISCOVERY, 2020, 10 (08) : 1091 - 1091
  • [26] Estimation of Long-Term Survival with Tafasitamab plus Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Salles, Gilles
    Goswami, Budhaditya
    Bagnardi, Vincenzo
    Dey, Debarshi
    Winderlich, Mark
    Ambarkhane, Sumeet
    Huang, Dan
    Nowakowski, Grzegorz S.
    BLOOD, 2020, 136
  • [27] L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years
    Duell, Johannes
    Jurczak, Wojciech
    Liberati, Anna Marina
    Halka, Janusz
    Carbo, Esther Pena
    Costa, Pau Abrisqueta
    Maddocks, Kami J.
    Dreyling, Martin
    Rosenwald, Andreas
    Bakuli, Abhishek
    Amin, Aasim
    Gurbanov, Konstantin
    Salles, Gilles
    BLOOD, 2022, 140 : 6596 - 6598
  • [28] Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
    Salles, Gilles
    Dlugosz-Danecka, Monika
    Ghesquieres, Herve
    Jurczak, Wojciech
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 455 - 463
  • [29] RE-MIND: A Comparison of Tafasitamab (MOR208) + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Rodgers, Thomas
    Zinzani, Pier Luigi
    Marino, Dario
    Frezzato, Maurizio
    Barbui, Anna Maria
    Castellino, Claudia
    Meli, Erika
    Conconi, Annarita
    Cascavilla, Nicola
    Cavallo, Federica
    Fowler, Nathan H.
    Feinberg, Bruce
    Tillmanns, Sascha
    Parche, Stephan
    Fingerle-Rowson, Gunter
    Winderlich, Mark
    Ambarkhane, Sumeet
    Salles, Gilles
    Nowakowski, Grzegorz
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S265 - S266
  • [30] Tafasitamab and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma in a patient on chronic intermittent hemodialysis
    Moore, Donald C.
    Eagers, Keren A.
    Janes, Amanda
    Pineda-Roman, Mauricio
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (01) : 239 - 241
12345